SOURCE: ChromoCure, Inc.

January 14, 2010 09:00 ET

ChromoCure Publishes Study of Effectiveness of Proprietary Cancer Detection Technology

RENO, NV--(Marketwire - January 14, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the publication of the Cervical Cancer Study, PRE-CLINICAL SYSTEM TESTING AND PERFORMANCE ASSESSMENT, conducted in conjunction with a major international Cancer Clinic. The study analyzed samples supplied by the Cancer Clinic with its Proprietary Chromosomal Scanner Technology (full text can be found @ The study demonstrated not only the correctness of the company's cancer detection approach but also the accuracy of the scan itself. The scanner performed perfectly with flawless detection results.

This exploratory study, using sub-optimal clinical samples, demonstrated:

1) the efficacy of using an automated system to detect aneuploid cells
   in real-world specimens;

2) the detection of aneuploid cells is diagnostic of cervical lesions; and

3) the scanner's superb performance at not only detecting cancer but
   achieving the near theoretical maximum agreement with error containing

Additionally, the Company's technology was reaffirmed and further confirmed by recent Mayo Clinic researchers. Their findings, which appear in the December 2009 issue of the journal Cancer Cell along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer. Given the new credibility of the chromosomal theory of cancer provided by the Mayo Clinic, the results of this performance study become immediately significant and relevant and further underscore both the correctness of the chromosomal basis of cancer as well as the performance of the company's technology.

These recent publications enhance the company's international activities to promote its cancer detection system and related technology through its ChromoCure Cancer Research & Diagnosis Centers program. The research further confirms the chromosomal theory of cancer and immediately establishes the company's technology in the forefront of both cancer detection and research.

ChromoCure's proprietary CS200 Chromosomal Scanner system and related technology is specifically designed to target the unique chromosomal characteristics demonstrated in the Mayo Clinic research. Detecting the unique chromosomal signature of cancer yields an effectively 100% accurate method of detecting all forms of cancer at all stages.

The company's systems detect the single characteristic found in 100% of all cancers at all stages, and never found in normal cells. The company therefore believes its technology detects cancer with an effective 100% specificity and effective 100% accuracy. The Company's technology also objectively measures, with high precision, the level of cancer present and its stage of progression.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information